Menu Back toTOPIC-5-RISK-MANAGEMENT
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Joint MHRA/DIA Excellence in Pharmacovigilance
TOPIC 5: RISK MANAGEMENT. SESSION 1: Risk Communication in EU – Challenges and Possibilities
Gaby L. Danan, MD, PhD
- Pharmacovigilance Expert
- GLD, France
- Group Manager, Vigilance, Intelligence and Research Group
- Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
In accordance with the GVP Module V on Risk Management System, risk management plans (RMPs) should be submitted by companies to propose activities aiming to identify, characterise or minimise risks associated with medicinal products. Given the potential public health implications and costs of such interventions, RMPs should be based on robust epidemiological methods that will be described and examples discussed in this session. This session aims also to provide the background for understanding drug-related risks, and to present recent developments regarding risk communication.
Risk Communication in EU – Challenges and Possibilities
- Institute of Pharmacovigilance, Czech Republic